Eplerenone is not superior to placebo for chronic central serous chorioretinopathy

Affiliations

¹ Department of Ophthalmology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan 20132, Italy. Electronic address: rabiolo.alessandro@gmail.com.
² Department of Ophthalmology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan 20132, Italy.

Comment

Alessandro Rabiolo et al. Lancet. 2020.

. 2020 Jan 25;395(10220):252-253.

doi: 10.1016/S0140-6736(19)33132-0.

¹ Department of Ophthalmology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan 20132, Italy. Electronic address: rabiolo.alessandro@gmail.com.
² Department of Ophthalmology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan 20132, Italy.

No abstract available

Comment on

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.
Lotery A, Sivaprasad S, O'Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC; VICI trial investigators. Lotery A, et al. Lancet. 2020 Jan 25;395(10220):294-303. doi: 10.1016/S0140-6736(19)32981-2. Lancet. 2020. PMID: 31982075 Clinical Trial.